Apremilast induced tinnitus: An unreported side effect.
作者信息
Sule Rajiv Ramesh, Choudhary Paras, Salunke Tejaswini Sopanrao
机构信息
Department of Dermatology, Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India.
出版信息
Indian J Pharmacol. 2021 Jul-Aug;53(4):328-329. doi: 10.4103/ijp.IJP_533_20.
Abstract
摘要
相似文献
1
Apremilast induced tinnitus: An unreported side effect.
Indian J Pharmacol. 2021 Jul-Aug;53(4):328-329. doi: 10.4103/ijp.IJP_533_20.
2
Appearance of lentigines in psoriasis patients treated with apremilast.
J Am Acad Dermatol. 2016 Dec;75(6):1251-1252. doi: 10.1016/j.jaad.2016.06.042.
3
An update on the safety of apremilast for the treatment of plaque psoriasis.
Expert Opin Drug Saf. 2020 Apr;19(4):403-408. doi: 10.1080/14740338.2020.1744562. Epub 2020 Mar 21.
4
Chronic tearing induced by apremilast.
Ann Allergy Asthma Immunol. 2018 Sep;121(3):375. doi: 10.1016/j.anai.2018.06.027. Epub 2018 Jun 30.
5
Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.
J Drugs Dermatol. 2021 May 1;20(5):582-583. doi: 10.36849/JDD.5730.
6
Improvement of 11 patients with nail psoriasis with apremilast: Results of an investigator-initiated open-label study.
J Am Acad Dermatol. 2020 Dec;83(6):1830-1832. doi: 10.1016/j.jaad.2020.05.087. Epub 2020 May 22.
7
Apremilast for the management of moderate to severe plaque psoriasis.
Expert Rev Clin Pharmacol. 2017 Apr;10(4):349-360. doi: 10.1080/17512433.2017.1293519. Epub 2017 Feb 17.
8
Otezla, Warts and All, Racks Up Sales and Eyes Blockbuster Status.
Manag Care. 2017 Oct;26(10):8-9.
9
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):397-402. doi: 10.1111/jdv.14738. Epub 2018 Jan 29.
10
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
J Am Acad Dermatol. 2016 Jul;75(1):99-105. doi: 10.1016/j.jaad.2016.02.1164. Epub 2016 Mar 24.
本文引用的文献
1
Safety evaluation of apremilast for the treatment of psoriasis.
Expert Opin Drug Saf. 2017 Mar;16(3):381-385. doi: 10.1080/14740338.2017.1288714. Epub 2017 Feb 7.
2
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Ann Rheum Dis. 2016 Jun;75(6):1065-73. doi: 10.1136/annrheumdis-2015-207963. Epub 2016 Jan 20.
3
Apremilast: first global approval.
Drugs. 2014 May;74(7):825-37. doi: 10.1007/s40265-014-0218-4.
4
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
Biochem Pharmacol. 2012 Jun 15;83(12):1583-90. doi: 10.1016/j.bcp.2012.01.001. Epub 2012 Jan 10.
5
Drug-induced tinnitus and other hearing disorders.
Drug Saf. 1996 Mar;14(3):198-212. doi: 10.2165/00002018-199614030-00006.
Zotero 插件